Linwah Yip

Linwah Yip

Auto-generated profile, based on publicly available information

Linwah Yip

Division of Endocrine Surgery, Department of Surgery, University of Pittsburgh , Pittsburgh, Pennsylvania

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2013 in The Oncologist
Verified
Journal Article
Closed access
GHGina M. Howell
Gina M. Howell
SHSteven P. Hodak
Steven P. Hodak
LYLinwah Yip
Linwah Yip
Learning Objectives: Explain the role of RAS mutations in thyroid carcinogenesis. Describe the histologic spectrum and prognostic implications of RAS-associated thyroid neoplasms. Explain the role of RAS mutation testing in patient care management algorithms.

1 December 2009 in Surgery
Verified
Journal Article
Closed access
LYLinwah Yip
Linwah Yip
MNMarina N. Nikiforova
Marina N. Nikiforova
SCSally E. Carty
Sally E. Carty
JYJohn H. Yim
John H. Yim
MSMichael T. Stang
Michael T. Stang
YNYuri E. Nikiforov
Yuri E. Nikiforov

1 June 2012 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
LYLinwah Yip
Linwah Yip
CFCoreen Farris
Coreen Farris
AKAdam S. Kabaker
Adam S. Kabaker
SHSteven P. Hodak
Steven P. Hodak
MNMarina N. Nikiforova
Marina N. Nikiforova
SCSally E. Carty
Sally E. Carty
Introduction: Molecular testing of fine-needle aspiration (FNA) results helps diagnose thyroid cancer, although the additional cost of this adjunct has not been studied. We hypothesized that FNA molecular testing of two indeterminate categories (follicular lesion of undetermined significance and follicular/Hürthle cell neoplasm) can be cost saving. Methods: For a hypothetical group of euthyroid patients with a 1-cm or larger solitary thyroid nodule, a decision-tree model was constructed to compare the estimated costs of initial evaluation according to the current American Thyroid Association guidelines, either with molecular testing (MT) or without [standard of care (StC)]. Model endpoints were either benign FNA results or definitive histological diagnosis. Results: Molecular testing added $104 per patient to the overall cost of nodule evaluation (StC $578 vs. MT $682). In this distributed cost model, MT was associated with a decrease in the number of diagnostic lobectomies (9.7% vs. StC 11.6%), whereas initial total thyroidectomy was more frequent (18.2% vs. StC 16.1%). Although MT use added a diagnostic cost of $5031 to each additional indicated total thyroidectomy ($11,383), the cumulative cost was still less than the comparable cost of performing lobectomy ($7684) followed by completion thyroidectomy ($11,954) in the StC pathway, when indicated by histological results. In sensitivity analysis, savings were demonstrated if molecular testing cost was less than $870. Conclusions: Molecular testing of cytologically indeterminate FNA results is cost saving predominantly because of reduction in two-stage thyroidectomy. Appropriate use of emerging molecular testing techniques may thus help optimize patient care, improve resource use, and avoid unnecessary operation.

1 September 2015 in Annals of Surgery
Verified
Journal Article
Closed access
LYLinwah Yip
Linwah Yip
MNMarina N. Nikiforova
Marina N. Nikiforova
JYJenny Y. Yoo
Jenny Y. Yoo
KMKelly L. McCoy
Kelly L. McCoy
MSMichael T. Stang
Michael T. Stang
SCSally E. Carty
Sally E. Carty
Objectives: To correlate thyroid cancer genotype with histology and outcomes. Background: The prognostic significance of molecular signature in thyroid cancer (TC) is undefined but can potentially change surgical management. Methods: We reviewed a consecutive series of 1510 patients who had initial thyroidectomy for TC with routine testing for BRAF, RAS, RET/PTC, and PAX8/PPARG alterations. Histologic metastatic or recurrent TC was tracked for 6 or more months after oncologic thyroidectomy. Results: Papillary thyroid cancer (PTC) was diagnosed in 97% of patients and poorly differentiated/anaplastic TC in 1.1%. Genetic alterations were detected in 1039 (70%); the most common mutations were BRAFV600E (644/1039, 62%), and RAS isoforms (323/1039, 31%). BRAFV600E-positive PTC was often conventional or tall cell variant (58%), with frequent extrathyroidal extension (51%) and lymph node metastasis (46%). Conversely, RAS-positive PTC was commonly follicular variant (87%), with infrequent extrathyroidal extension (4.6%) and lymph node metastasis (5.6%). BRAFV600E and RET/PTC-positive PTCs were histologically similar. Analogously, RAS and PAX8/PPARG-positive PTCs were histologically similar. Compared with RAS or PAX8/PPARG-positive TCs, BRAFV600E or RET/PTC-positive TCs were more often associated with stage III/IV disease (40% vs 15%, P < 0.001) and recurrence (10% vs 0.7%, P < 0.001; mean follow-up 33 ± 21 mo). Distant metastasis was highest in patients with RET/PTC-positive TC (10.8%, P = 0.02). Conclusions: In this large study of prospective mutation testing in unselected patients with TC, molecular signature was associated with distinctive phenotypes including cancers, with higher risks of both distant metastasis and early recurrence. Preoperative genotype provides valuable prognostic data to appropriately inform surgery.

1 October 2013 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
LWLaura I. Wharry
Laura I. Wharry
KMKelly L. McCoy
Kelly L. McCoy
MSMichael T. Stang
Michael T. Stang
MAMichaele J. Armstrong
Michaele J. Armstrong
SLShane O. LeBeau
Shane O. LeBeau
LYLinwah Yip
Linwah Yip

1 September 2012 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
GHGina M. Howell
Gina M. Howell
MNMarina N. Nikiforova
Marina N. Nikiforova
SCSally E. Carty
Sally E. Carty
MAMichaele J. Armstrong
Michaele J. Armstrong
SHSteven P. Hodak
Steven P. Hodak
LYLinwah Yip
Linwah Yip